P-SPHERE This programme will offer 3 years postdoctoral fellowship to a total of 48 experienced researchers under Cofund Marie Skłodowska-Curie Actions

Petter Sutton

   Peter Sutton
   Postdoctoral Researcher


Phone no.
+34 93 581 1018

Departament d’enginyeria Química, Biològica i Ambiental
Àrea d’Enginyeria Química
Edifici Q, Carrer de les Sitges
08193 Bellaterra (Cerdanyola del Vallès)

A synthetic chemist by background, gaining his PhD from the University of Exeter (1995) in the group of Professor Stanley M. Roberts. He received his postdoctoral training in the medicinal chemistry group of Professor Chris McGuigan working on the development of nucleotide prodrugs at the University of Wales, Cardiff (1995-1998) before joining the group of Professor Jaume Vilarrasa at the University of Barcelona as a member of a European TMR network designing new asymmetric catalysts (1998-2000).

He later gained industrial expertise in chemoenzymatic synthesis within a small UK-based biotech contract research and development company (2000-2005) before moving to GlaxoSmithKline where he focussed on the identification, development and scale-up of biocatalytic processes (2005-2016).

A co-editor of the “Practical Methods for Biocatalysis and Biotransformations” book series (2010-Current), he has since taken up a P-Sphere Postdoctoral Fellowship position at the Universitat Autònoma de Barcelona funded through the European Union’s Horizon 2020 research and innovation programme under Marie Skłodowska-Curie grant agreement No 665919.

The identification, development and scale-up of novel, sustainable bioprocesses of industrial value.

  • Development of an Enzymatic Process for the Production of (R)-2-Butyl-2-ethyloxirane, G.-D. Roiban, P. W. Sutton, R. Splain, C. Morgan, A. Fosberry, K. Honicker, P. Homes, C. Boudet, A. Dann, J. Guo, K. K. Brown, L. A. F. Ihnken and D. Fuerst. Org. Proc. Res. Dev. 2017, 21, 1302.
  • New Technologies in Process Development, P. W. Sutton, J. P. Adams, C. Wade and K. Wheelhouse in Early Drug Development – From A Drug Candidate to the Clinic, F. Giordanetto, R. Mannhold and H. Buschmann (Eds), 2018, Wiley-VCH.
  • Highly selective enzymatic amoxicillin synthesis, Brown, Murray; Chapman, Ted; Chaudry, Laiq; Davis, Isabelle; Edge, Colin; Fosberry, Andrew; Gee, Michelle; Hayes, Simon; Jones, Emma; Joyce, Lucy; Leavens, Bill; Shipton, Mark; Smith, Dominic; Sutton, Peter W.; Wade, Charles, IP.com Journal, 201313, 8A, 1-4.  
  • Biocatalysis in the fine chemical and pharmaceutical industries, P. W. Sutton, J. P. Adams, I Archer, D. Auriol, M. Avi, C. Branneby, A. J. Collis, B. Dumas, T. Eckrich, I. Fotheringham, et al. in Practical Methods for Biocatalysis and Biotransformations, 2012, 1-59.
  • Biotransformations in small-​molecule pharmaceutical development, J. P. Adams, A. J. Collis, R. K. Henderson, P. W. Sutton in Practical Methods for Biocatalysis and Biotransformations, 2010, 1-82.

  • N-​Alkyl-​α-​amino acids in Nature and their biocatalytic preparation, J. F. Hyslop, S. L. Lovelock, A. J. B. Watson, P. W. Sutton and  G.-D. Roiban, J. Biotechnol. 2019, 293, 56.